Use of proton pump inhibitors (PPI) in adults with asthma is unlikely to have clinical significance, a study reveals.
US researchers found PPI therapy in adults resulted in a small statistically significant improvement in morning peak expiratory flow (PEF), but noted it had little benefit on the evening PEF rate, forced expiratory volume (FEV) or quality of life.
The meta-analysis, which included 2167 patients revealed the improvements in PEF in patients treated with routine PPI compared with a placebo were greater in patients diagnosed with gastro-esophagael reflux disease (GERD).
“Our results fall below the range of minimal patient perceived improvement for PEF rate as well as improvements seen with other medical therapies, suggesting minimal clinical benefits for routine asthma care,” the authors said.
This site is intended for Registered Medical Practitioners.
To make the most of Pharmacy News, you need to be logged in.